Introduction: Little is known about long-term survivors after complete resection of non-small cell lung cancer. Therefore, this study clarified the characteristics of 10-year-plus postoperative survivors with postoperative recurrence.
Materials and Methods: From January 1999 to December 2010, eleven 10-year-plus survivors had recurrence after lobectomy or greater resection for non-small cell lung cancer in our hospital. We analyzed this population retrospectively.
Results: The mean patient age was 64 years, and ten patients had adenocarcinoma. In the top eight long-surviving patients, recurrence developed within 4 years after surgery, and the recurrence was oligometastatic or dormant. However, there was no correlation between recurrence-free and post-recurrence survival. Patients with oligometastases tended to have received radical local therapy or short-term treatment sequences and to have developed recurrence within a few years after surgery. Driver gene-positive patients tended to have distant and multiple metastases. EGFR-positive, tyrosine kinase inhibitor-treated patients died within 84 months.
Summary: Oligometastatic recurrence cases might be included in the “cured” population; an oligometastatic status might be equivalent to stage III rather than stage IV. Patients with a dormant or oligometastatic state tended to survive longer, while EGFR-positive patients survived only until they became resistant to tyrosine kinase inhibitor (cytostatic) agents. Therefore, cytotoxic agents should be added to the treatment from a long-term perspective.
抄録全体を表示